Alpha-bisabolol for Onychomycosis Treatment - Trial NCT04940520
Access comprehensive clinical trial information for NCT04940520 through Pure Global AI's free database. This Phase 1 trial is sponsored by Universidade do Vale do Sapucai and is currently Completed. The study focuses on Onychomycosis. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Universidade do Vale do Sapucai
Timeline & Enrollment
Phase 1
Jun 01, 2020
May 01, 2021
Primary Outcome
Injury area analysis
Summary
Clinical, interventional, longitudinal study with random sampling. 60 patients will be
 divided into three groups, group A: control group, drug recommended by the Brazilian Society
 of Dermatology, group B: alpha bisabolol-based product associated with low-level laser
 therapy, and group C: alpha bisabolol based product. The topical application will be
 performed twice a day, while the laser application and photographs of the lesions, every 15
 days. Areas of the lesions will be compared.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04940520
Non-Device Trial